Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4391436 | 1.00 | RECQL (0.49) | RECQLNPSR1AKR1B1CYP19A1MAOA | |
| SCHEMBL4391442 | 1.00 | RECQL (0.49) | RECQLNPSR1AKR1B1CYP19A1MAOA | |
| SCHEMBL9046968 | 0.84 | RECQL (0.50) | RECQLMAOAMAOBALDH1A1MAPT | |
| SCHEMBL9046985 | 0.84 | RECQL (0.50) | RECQLMAOAMAOBALDH1A1MAPT | |
| SCHEMBL9046977 | 0.84 | RECQL (0.50) | RECQLMAOAMAOBALDH1A1MAPT | |
| SCHEMBL1915838 | 0.83 | RECQL (0.69) | RECQLCYP3A4MAPTMEN1KMT2A | |
| SCHEMBL1915834 | 0.83 | RECQL (0.69) | RECQLCYP3A4MAPTMEN1KMT2A | |
| SCHEMBL1915837 | 0.83 | RECQL (0.69) | RECQLCYP3A4MAPTMEN1KMT2A | |
| SCHEMBL9023565 | 0.83 | ALDH1A1 (0.55) | RECQLAKR1B1MAOBALDH1A1MAPT | |
| Benzene SCHEMBL27424700 | 0.83 | ALDH1A1 (0.55) | RECQLAKR1B1MAOBALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306201-A1 | SELECTIVE INHIBITORS FOR TRANSFERASES | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2009-12-10 | — | — | US | disclosed |
| WO-2007149782-A2 | SELECTIVE INHIBITORS FOR TRANSFERASES | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306201-A1 | SELECTIVE INHIBITORS FOR TRANSFERASES | TYMP, PCNA, TK1 | RECQL 506/4885NPSR1 4566/4885AKR1B1 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.